NASDAQ:INVA - Innoviva Stock Price, Price Target & More

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Innoviva (NASDAQ:INVA) issued its quarterly earnings results on Thursday, April, 26th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.50 by $0.23. The biotechnology company earned $52.40 million during the quarter, compared to analysts' expectations of $71.84 million. Innoviva had a negative return on equity of 63.57% and a net margin of 64.11%. The company's quarterly revenue was up 29.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.19 EPS. View Innoviva's Earnings History.

Innoviva is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Innoviva.

6 brokers have issued 12-month target prices for Innoviva's shares. Their forecasts range from $8.00 to $16.00. On average, they expect Innoviva's share price to reach $13.20 in the next twelve months. View Analyst Ratings for Innoviva.

Innoviva saw a decrease in short interest in the month of April. As of April 30th, there was short interest totalling 11,842,171 shares, a decrease of 11.3% from the April 13th total of 13,344,078 shares. Based on an average trading volume of 1,262,701 shares, the days-to-cover ratio is currently 9.4 days. Approximately 17.7% of the shares of the company are short sold.

Some companies that are related to Innoviva include Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), Catalent (CTLT), Agios Pharmaceuticals (AGIO), Loxo Oncology (LOXO), Dr. Reddy's Laboratories (RDY), Taro Pharmaceutical Industries (TARO), United Therapeutics (UTHR), GW Pharmaceuticals (GWPH), FibroGen (FGEN), Ligand Pharmaceuticals (LGND), Hutchison China MediTech (HCM), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE) and Array Biopharma (ARRY).

Media coverage about INVA stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Innoviva earned a daily sentiment score of 0.08 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.31 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Innoviva's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.68%), Dimensional Fund Advisors LP (1.69%), First Eagle Investment Management LLC (1.34%), Northern Trust Corp (1.01%), UBS Group AG (0.70%) and Victory Capital Management Inc. (0.63%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, Michael W Aguiar, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva.

INVA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., JPMorgan Chase & Co., Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Smith Asset Management Group LP, Systematic Financial Management LP, Camarda Financial Advisors LLC and Northern Trust Corp. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie and Michael W Aguiar. View Insider Buying and Selling for Innoviva.

INVA stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, Dimensional Fund Advisors LP, PNC Financial Services Group Inc., WINTON GROUP Ltd, Millennium Management LLC, Hsbc Holdings PLC, Algert Global LLC and Hussman Strategic Advisors Inc.. View Insider Buying and Selling for Innoviva.

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of INVA stock can currently be purchased for approximately $14.43.

Innoviva has a market capitalization of $1.47 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.17 on an earnings per share basis. Innoviva employs 12 workers across the globe.

Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]